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IDENTIFICATION OF THE LYSINE MET YLTR  




 Angiogenesis is the process of new blood vessel growth from preexisting 
vessels. This process relies on the activity of Vascular Endothelial Growth Factor 
Receptor-2 (VEGFR-2) and occurs in both normal and pathological tissues. 
Angiogenesis is often dysregulated in diseases such as cancer and many efforts 
have been made to treat such diseases by targeting the VEGFR-2 pathway. 
VEGFR-2 is activated upon ligand binding and subsequent autophosphorylation 
of tyrosine residues in the kinase domain, which leads to endothelial cell survival, 
proliferation, and growth – all of which are required for angiogenesis to occur.  
It was previously demonstrated that methylation of VEGFR-2 at Lys1041 
enhanced its tyrosine autophosphorylation and is required for VEGFR-2 
mediated angiogenesis in zebrafish and tumor growth in mouse. However, the 
Lysine Methyltransferase (KMT) involved in the methylation of VEGFR-2 remains 
unknown. This study aimed to identify the KMT involved in the methylation of 
VEGFR-2. 
We have identified Enhancer of zeste homolog 2 (EZH2) as the KMT likely 
responsible for catalyzing methylation of K1041 on VEGFR-2.  Over-expression 
of EZH2 was found to increase phosphorylation of Tyr1054, one of the required 
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phosphorylation sites for VEGFR-2 activation, in whole cell lysates and VEGFR-2 
purified by immunoprecipitation. The effect of over-expression of EZH2 in the 
phosphorylation of VEGFR-2 at Tyr1054 was dose-dependent - increasing 
concentrations of EZH2 resulted in increasing phosphorylation of VEGFR-2 at 
Tyr1054. Moreover, we determined that EZH2 physically interacts with VEGFR-2 
as demonstrated by co-immunoprecipitation in vitro GST-pulldown assays. The 
C-terminus of EZH2 (amino acids 371-746), physically interacted with VEGFR-2. 
Taken together, we have identified EZH2 as a candidate KMT involved in the 
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Vasculogenesis and angiogenesis are essential functions in both normal 
and pathological tissues. Vasculogenesis involves the de novo formation of blood 
vessels following differentiation of angioblasts or stem cells during embryonic 
development. Angiogenesis involves the branching and extension of preexisting 
blood vessels during embryonic development and throughout the adult life. 
These processes, which create and maintain steady blow flow to the organs and 
tissues of the body, are necessary to sustain life. 
Angiogenesis occurs in four stages – blood vessel formation, stabilization, 
branching and remodeling, and specialization (Jain, 2003). Angiogenesis starts 
when some endothelial cells (ECs), called tip cells, detect pro-angiogenic signals 
such as VEGF ligand and angiopoietin-2, which are increased in response to 
hypoxic conditions. These signals, along with others, cause ECs to loosen their 
cell-cell junctions, degrade the extracellular matrix, and become more motile. 
Endothelial tip cells extend filopodial protrusions in order to facilitate the growth 
of newly sprouting vessels. These extensions sense attractive and repulsive 
signals in the microenvironment, which help guide the tip cells. The majority of 
ECs in angiogenesis are stalk cells which trail the tip cells. These stalk cells are 
less motile and thus generate the bulk of the new vessels and help to maintain a 
connection with preexisting vessels. (Herbert and Stainier, 2011) This process of 
formation and sprouting continues until tip cells connect with other vessels and 
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undergo anastomosis, at which time the tip cells cease to be motile and create 
stronger cell-cell junctions with adjacent ECs.  
Stabilization of ECs involves recruiting mural cells and generating the 
extracellular matrix (ECM). Mural cells are precursors for smooth muscle cells 
and pericytes, which both wrap around ECs to stabilize the vessel. Several 
pathways regulate stabilization. Platelet derived growth factor (PDGF) is 
expressed by both ECs and mural cells and is partly responsible for mural cell 
recruitment, proliferation, and migration (Jain, 2003). Additionally, the endothelial 
differentiation sphingolipid G-protein-coupled-receptor 1 (EDG1), which is 
expressed on mural cells, is involved in mural cell migration. PDGF and EDG1 
knockout mice both fail to have sufficient mural cell migration and thus reduced 
pericyte stabilization (Cho, 2003).  
Branching, remodeling, and pruning allow blood vasculature to obtain its 
optimal structure within the organ (Jain, 2003). Metalloproteinases, or MMPs, 
degrade the basement membrane and ECM, which allows the ECs to migrate. 
MMPs also help to release pro-angiogenic growth factors, such as vascular 
endothelial growth factor (VEGF) and insulin like growth factor-1 (IGF-1) 
(Conway et al., 2001), anti-angiogenic molecules, and matrix molecules, which 
all together regulate proliferation and apoptosis of ECs and mural cells (Jain, 
2003). As ECs extend they arrange into cord like structures and then acquire a 
lumen.   
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Lastly, vessel specialization determines whether vessels become arteries, 
veins, or capillaries. Arteries tend to carry oxygenated blood away from the heart 
while veins tend to carry deoxygenated blood from the tissues of the body back 
to the heart, with the exception of pulmonary arteries and veins which do the 
opposite. Capillaries are the primary site for oxygen, nutrient, and waste 
exchange between the blood and the tissues of the body. Capillaries have the 
simplest structure: ECs surrounded by a basement membrane and few pericytes. 
Both arteries and veins have a more complex structure including vascular 
smooth muscle, pericytes, elastic lamina, and extracellular matrix. It has been 
suggested that arterio-venous specification is due to genetic factors, rather than 
shear stress created by blood flow as previously believed. Active Notch signaling 
promotes expression of transcription factors, which leads to arterial formation 
(Fischer et al., 2004), while repression of Notch promotes venous differentiation 
(You et al., 2005). Additional differentiation can form organ-specific capillary 
structures (Jain, 2003).  
 
Role of Angiogenesis in Human Health and Diseases 
Angiogenesis is critical for tissue survival due to the constant need for 
blood flow to oxygenate tissues and remove potentially toxic waste. Both normal 
and pathological tissues rely on the processes described above to extend blood 
flow, however pathological tissues often rely on dysregulated angiogenic factors, 
which can lead to a multitude of diseases. Age related macular degeneration 
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(AMD) and diabetic retinopathy are both in part caused by increased vascular 
endothelial growth factor (VEGF), a proangiogenic signal (Witmer et al., 2005). 
Cancer, tumor progression, and metastasis are also exacerbated by 
angiogenesis (Carmeliet, 2003). In order for a solid tumor to grow greater than 
2mm in diameter, angiogenesis must occur to supply blood and thus nutrients to 
the growing mass (Bergers and Benjamin, 2003). Additionally, the leaky 
vasculature that often accompanies pathological angiogenesis supports 
metastatic cancer growth (Cooke et al., 2012).  
Because of the close ties between angiogenesis and cancer progression, 
many pharmaceutical companies have developed anti-angiogenic 
pharmaceutical products to aid in cancer treatment. Currently, there are eleven 
anti-VEGF drugs FDA approved to inhibit angiogenesis and thus treat a wide 
variety of advanced cancers (Ramijawan et al., 2017). Unfortunately, many of 
these drugs have limited positive results. Initially, drugs were designed to block 
pro-angiogenic factors and hence disrupt the vascular supply, but this resulted in 
increased tumor hypoxia and challenges with drug delivery to the tumor site. 
Increased tumor hypoxia resulted in increased tumor migration and inflammation, 
which ultimately caused rapid progression of the tumor (Jain, 2005). More 
recently the goal of anti-angiogenic drugs has been to normalize the tumor 
vasculature, which has been successful in improving the survival of patients with 
brain, breast, colorectal, and lung cancers (Batchelor et al., 2007; Tolaney et al., 
2015; Kabbinavar et al., 2003; Heist et al., 2015). Moreover, many cancers 
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develop resistance to these drugs. The exact mechanisms for resistance is not 
fully understood, but it is believed that other angiogenic pathways are activated, 
which ultimately promote tumor vasculature (van Beijnum et al., 2015). There are 
many new drugs currently being developed and undergoing clinical trials. A 
better understanding of the mechanisms of Vascular Endothelial Growth Factor 
Receptor-2 (VEFGR-2) kinase activation, such as the role of novel 
posttranslational lysine/arginine methylation, may lead to additional drug targets.  
 
Role of Vascular Endothelial Growth Factor Receptor-2 in Angiogenesis  
VEGFR-2 is a member of the receptor tyrosine kinase (RTKs) family. 
VEGFR-2 consists of an extracellular ligand binding domain, a transmembrane 
domain, a juxtamembrane domain, a single kinase domain broken into two parts 
separated by a kinase insert, and a C-terminal region (Rahimi, 2006). VEGFR-2 
and its ligand, VEGF, play a crucial role in angiogenic signaling. VEGFR-2 
activation begins when a ligand binds the extracellular immunoglobulin 
containing domain. Ligand binding causes subsequent receptor dimerization. 
VEGFR-2 is involved in both homo-dimerization and hetero-dimerization. After 
dimerization occurs the RTK undergoes autophosphorylation. In the resting, 
inactive state VEGFR-2’s ATP binding pocket is physically inhibited within the 
activation loop of the kinase domain (Schlessinger, 2003). The first 
autophosphorylation event occurs on tyrosine sites in the activation loop - Y1054 
and Y1059 in mouse and Y1052 and Y1057 in human, which subsequently 
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relieve the inhibition on the kinase activation loop (Hubbard et al., 1998). This 
autophosphorylation is critical for VEGFR-2 kinase activation. Additional 
autophosphorylation sites are within the juxtamembrane domain, kinase domain 
and insert, and C-terminal domain, all of which generate future docking sites for 
other cytoplasmic, downstream proteins (Hubbard and Till, 2000).  
VEGFR-2 is predominantly expressed in vascular endothelium during 
embryonic development, highlighting its critical role in endothelial cell 
development and hence vasculogenesis and angiogenesis (Quinn et al., 1993). 
VEGFR-2 knockout mice die in utero as a result of a defect in endothelial cell 
development causing no apparent organized blood vessels (Shalaby et al., 
1995). Similarly, VEGF knockout and deficient mice die in utero as a result of 
defected endothelial development, however heterozygote VEGF deficient mice 
have some organized, but abnormal blood vessel development (Carmeliet et al., 
1996). These early studies highlight the importance of VEGFR-2 and VEGF in 
vasculogenesis and angiogenesis. 
 VEGFR-2 stimulates a broad array of signaling proteins such as 
Phosphoinositide 3-kinase (PI3K) and phospholipase C𝛾1 (PLC𝛾1). PI3K 
contains a src homology 2 (SH2) domain which recognizes phosphorylated 
tyrosine docking sites in the juxtamembrane and kinase domains of VEGFR-2. 
PI3K is a lipid kinase that gets recruited to the plasma membrane upon VEGFR-2 
activation. Once PI3K is recruited it comes in contact with phosphatidylinositol 
4,5-bisphosphate (PIP2), a lipid component of the plasma membrane. PI3K 
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catalyzes the phosphorylation of PIP2, making it PIP3. PIP3 contains a docking 
site for proteins containing the pleckstrin-homology (PH) domain. Protein kinase 
B, or Akt, and phosphoinositide-dependent kinase 1 (PDK1) are both recruited to 
the plasma membrane through their PH domains. PDK1 phosphorylates and 
activates Akt, which then goes on to phosphorylate several other proteins 
affecting cell growth, cell cycle entry, and cell survival (Cantley, 2002). Active Akt 
is sufficient for survival of serum-starved endothelial cells, hence its importance 
in promoting angiogenesis, which relies on the survival and proliferation of 
endothelial cells (Gerber et al., 1998). There are several other studies 
demonstrating the importance of PI3K and Akt in endothelial cell survival and 
proliferation, and hence, angiogenesis (Rahimi, 2006). When PI3K is inhibited by 
wortmannin, a potent inhibitor of PI3K, or a dominant negative form of p85, there 
is reduced MAP kinase activity in response to VEGFR-2 stimulation resulting in 
reduced entry into the synthesis phase and subsequent reduced endothelial cell 
proliferation (Thakker et al., 1999). Overexpression of PTEN, a lipid phosphatase 
that dephosphorylates PIP3, inhibits VEGF-mediated endothelial cell 
proliferation. Overexpression of an inactive form of PTEN, which ultimately allows 
PIP3 to accumulate, results in enhanced VEGF-mediated endothelial cell 
proliferation (Huang and Kontos, 2002). As demonstrated by these studies, 
VEGFR-2 activation of PI3K and downstream activation of Akt are responsible for 
endothelial cell survival and proliferation, the benchmarks of angiogenesis.  
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 Tyrosine phosphorylation sites in the kinase domain also create docking 
sites for the recruitment of phospholipase C𝛾1 (PLC𝛾1) through an SH2 domain 
(Meyer et al., 2003). PLC𝛾1 plays an important role in VEGFR-2 signaling and 
angiogenesis (Meyer et al., 2011). PLC𝛾1 knock-out zebrafish have severe 
defects in vasculogenesis causing death (Lawson et al., 2003). PLC𝛾1cleaves 
phosphoinositides creating 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). 
IP3 is a second messenger that interacts with calcium channels on the 
endoplasmic reticulum membrane causing subsequent release of Ca2+. An 
increase in intracellular Ca2+ activates several calcium dependent proteins, such 
as calmodulin. DAG activates protein kinase C (PKC) (Sekiya et al., 1999), which 
plays a critical role in cell growth, proliferation, and survival (Moscat and Diaz-
Meco, 2000). PKC mediates activation of the Raf-MEK-MAP kinase in endothelial 
cells and thus entry into the S phase and subsequent proliferation of ECs 
(Takahashi et al., 1999). VEGFR-2’s role in promoting DNA synthesis and EC 
proliferation and growth demonstrates another way this RTK induces 
angiogenesis (Ferrara et al., 2003).  
   
Posttranslational Modifications of VEGFR-2 
 VEGFR-2 undergoes several posttranslational modifications (PTM) – 
glycosylation, acetylation, ubiquitination, phosphorylation, and methylation 
(Rahimi and Costello, 2015).  N-linked glycosylation is a PTM that occurs on the 
extracellular domain of VEGFR-2 and is necessary for efficient trafficking of 
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VEGFR-2 to the cell surface (Nacev et al., 2011) and for ligand binding and thus 
activation of the receptor (Takahashi and Shibuya, 1997).  
The most extensively studied PTM is phosphorylation. The intracellular 
domain of VEGFR-2 contains 19 possible Tyrosine phosphorylation sites 
(Matsumoto et al., 2005), as well as Threonine and Serine phosphorylation sites. 
These phosphorylation sites exist in the juxtamembrane domain, kinase domain, 
kinase insert, and C-terminal domain. Two Tyrosine phosphorylation sites in the 
kinase domain, Y1054 and Y1059 in mouse, are autophosphorylated following 
ligand binding and are required for maximal VEGFR-2 kinase activity (Dougher 
and Terman, 1999). Other phosphorylated sites are critical for VEGFR-2 and its 
downstream activity, such as Y1175, and its crucial role in activating PLC𝛾1 by 
creating an SH2 domain (Takahashi et al., 2001). Methylation of VEGFR-2 
occurs on both Lysine and Arginine residues within the juxtamembrane and 
kinase domains. Five methylated sites have been identified on VEGFR-2 by 
mass spectrometry analysis – Arg817, Lys856, Lys861, Lys1041, and Arg1115 
(Hartsough et al., 2013). Methylation of Lys1041 significantly enhances tyrosine 
phosphorylation and VEGFR-2 kinase activation, which will be explored further in 






Figure 1: Schematic of VEGFR-2 Including Methylation Sites. 
Structure of VEGFR-2 showing extracellular domain, transmembrane domain, 
and kinase domain. Five methylation sites are indicated - R817, K856, K861, 
K1041, and R1115. ATP binding site K866 and autophosphorylation sites Y1052 
and Y1059 in activation loop are also shown. (Hartsough, 2012) 
 
Protein Lysine and Arginine Methyltransferases  
 Protein methylation occurs on the side chains of Lysine and Arginine 
residues and can regulate protein-protein interactions and protein activity. 
Arginine methyltransferases (PRMT) catalyze Arginine methylation. Lysine 
methylation is catalyzed by Lysine methyltransferases (KMT). There are three 
classes of methyltransferases – Class I enzymes have a common seven-
stranded b-sheet structure and include PRMTs, Class II enzymes have a SET 
domain and include KMTs, and Class III enzymes include the membrane-
associated methyltransferases (Katz et al., 2003). Both PRMTs and KMTs use S-
adenosylmethionine (SAM) as the methyl donor resulting in the formation of a 
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methylated protein and S-adenosylhomocysteine (SAH). PRMTs can add one or 
two methyl groups creating mono-, or di-methylarginine. Di-methylarginine exists 
in either the asymmetric form (aDMA) or the symmetric form (sDMA), catalyzed 
by type I PRMTs and type II PRMTs respectively (Bedford and Richard, 2005). 
All three types of PRMTS, type I, II, and III can catalyze the formation of mono-
methylarginine. Asymmetric di-methylarginine has two methyl groups attached to 
the same terminal guanido group in the Arginine side chain, while symmetric di-
methylarginine has a single methyl group attached to each of the two terminal 
guanido groups in the Arginine side chain. KMTs can add one, two, or three 
methyl groups to the epsilon-amino group of the lysine side chain creating  






Figure 2: Protein Methylation Pathways. A) Protein Arginine Methyl 
Transferases (PRMT) type I, II, and III. PRMTs can add one or two methyl 
groups creating mono-methylarginine, asymmetric di-methylarginine, and 
symmetric di-methylarginine. PRMTs use SAM as the methyl donor. B) Lysine 
Methyl Transferases (KMT) can add one, two, or three methyl groups creating 
mono-, di-, or tri-methyllysine. KMTs use SAM as a methyl donor (Rahimi and 
Costello, 2015). 
 
 Currently there are 10 PRMTs identified (Bedford, 2007). Historically these 
were thought of as house-keeping enzymes, but recently they are known to have 
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more significant functions. PRMT1, 2, 3, 4, 6, and 8 are type I PRMTs, creating 
aDMAs. PRMT5 and 9 are type II PRMTs, creating sDMAs. PRMT7 is a type III 
PRMT catalyzing the formation of mono-methylarginine. (Cura et al., 2017) 
PRMT’s contain a THW loop and four conserved sequence motifs – I, post-I, II, 
and III (Katz et al., 2003). Conserved motifs I, post-I, and the THW loop 
constitute the SAM binding pocket (Zhang et al., 2000). PRMT enzymes work on 
a diverse set of substrates, which highlights the ubiquity of arginine methylation. 
PRMT1 and PRMT4 have been shown to have a necessary function in 
developing organisms – PRMT1 and PRMT4 mouse knockouts resulted in early 
embryonic death (Pawlak et al., 2000; Yadav et al., 2003). Additionally, PRMT1 
and PRMT4 knockdowns had differentially reduced methylation indicating 
substrate specificity and limited back-up methylation mechanisms.  
 There are over 48 known Lysine methyltransferases, KMTs, with the 
majority containing a conserved catalytic domain, called the SET domain – 
Suppressor of variegation, Enhancer of Zeste, Thirthorax (Albert and Helin, 
2010). These KMTs use SAM as a methyl donor and catalyze the formation of 
mono-, di-, or tri-methyllysine (Zhang et al., 2012). KMTs are specific as to 
whether they add one, two, or three methyl groups. Within the KMT SET domain 
active site there is either a Phenylalanine residue or a Tyrosine residue. The 
identity, Phe or Tyr, at the specific site determines whether the KMTs catalyzes 
mono-methylation or di- and tri-methylation (Collins et al., 2005). Enzymes that 
have a Phenylalanine, or other hydrophobic residue, catalyze the formation of di- 
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and tri-methyllysine while enzymes with a Tyrosine residue catalyze the 
formation of mono-methyllysine (Del Rizzo et al., 2010). Lysine methylation is a 
ubiquitous cellular event. 
 
Methylation as an Emerging Posttranslational Modification 
 Methylation of Arginine and Lysine residues on proteins can control 
protein-protein interactions, enzymatic activity of RTKs, protein phosphorylation, 
and subsequently protein function (Rahimi and Costello, 2015). Historically, 
histone methylation was the most prominent posttranslational methylation. 
Methylation of histones plays a large role in epigenetics, which is the modification 
of gene expression without altering the genetic code. DNA is packaged in a 
condensed structure called a nucleosome, which is made up of DNA bound to 4 
histone proteins – H2A, H2B, H3, and H4A (Bell et al., 2011). Posttranslational 
modifications, such as acetylation, ubiquitination, phosphorylation, and 
methylation affect the structure of the histone proteins and their affinity to bind 
DNA. Heterochromatin refers to tightly bound, repressed DNA, whereas 
euchromatin refers to DNA which is more loosely bound and accessible for 
transcription (Bell et al., 2011). Methylation of histone H3 at Lysine sites 4, 36, or 
79 is associated with euchromatin, DNA that is accessible for transcription, but 
methylation of H3 at Lysine 20 is associated with heterochromatin and 
suppression of transcription (Bell et al., 2011). Methylation, in regards to histone 
proteins, plays a clear role in controlling protein function.  
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 More recently it has been shown that non-histone proteins also have 
methylated Lysine and Arginine sites (Bedford and Richard, 2005; Huang and 
Berger, 2008). As is the case with the SH2 domain, which recognizes a 
phosphorylated Tyrosine, many protein domains recognize a methylated Arginine 
or Lysine site - the chromo domain, PHD domain, Tudor domain, MBT domain, 
and WD40 domain (Rahimi and Costello, 2015). These domains recognize and 
interact with methylated Arg and Lys sites, hence methylation as a PTM 
controlling protein-protein interactions. Alternatively, methylation of Lysine and 
Arginine residues can block protein-protein interactions, as is the case with 
methylated Arg on Sam68 which ultimately blocks its interaction with Src family 
kinases through an SH3 domain (Bedford et al., 2000). Additionally, methylation 
of tumor suppressor p53 affects target gene specificity, blocking binding with 
certain genes, and can thus regulate apoptosis and cell-cycle arrest (Jansson et 
al., 2008; Shi et al., 2007).  
 Non-histone protein methylation also affects protein function by playing a 
role in controlling protein phosphorylation. Forkhead transcription factors of class 
O (FOXO) are a family of transcription factors primarily found in the nucleus that 
play a role in regulating genes that induce apoptosis, control the cell cycle, 
regulate glucose metabolism, and promote resistance to oxidative stress (Greer 
and Brunet, 2005). The PI3K-Akt signaling pathway negatively controls FOXO 
transcription factors (Yamagata et al., 2008). Normally, Akt phosphorylates 
FOXO proteins resulting in cytoplasmic localization and degradation. FOXO 
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transcription factors can be methylated by PRMT1 at Arg248 and Arg250. 
Methylation at these sites directly blocks Akt-mediated phosphorylation at 
Ser253, which leads to nuclear accumulation of FOXO transcription factors 
resulting in increased oxidative-stress induced apoptosis (Yamagata et al., 
2008).  
Cytoplasmic and membrane bound proteins also have methylation sites 
that control downstream protein phosphorylation and thus protein function. 
Epidermal growth factor receptor (EGFR) is methylated at Arg1175 by PRMT5 
(Hsu et al., 2011). Methylation at this site positively modulates ligand induced 
EGFR autophosphorylation at Tyr1173, which controls downstream MAP 
activation (Hsu et al., 2011). Vascular endothelial growth factor 1, VEGFR-1, is 
methylated at Lys831 by SMYD3 (Kunizaki et al., 2007). Methylation at this site 
was shown to increase kinase activity of the receptor tyrosine kinase (Kunizaki et 
al., 2007). Unlike VEGFR-2, VEGFR-1 typically has low kinase activity and can 
both stimulate and inhibit angiogenesis (Meyer et al., 2006; Park et al., 2016).  
VEGFR-2 plays a crucial role in promoting angiogenesis, as previously 
discussed, and is also methylated at multiple Arginine and Lysine residues. To 
date there are five methylation sites on VEGFR-2 identified by mass 
spectrometry analysis – Arg817, Lys856, Lys861, Lys1041, and Arg1115 
(Hartsough et al., 2013). Lys856 and Lys861 are both located in the C-loop of the 
intracellular kinase domain of the RTK, upstream of the ATP binding site. 
Lys1041 is located between the two b-sheets of the kinase domain. (Hartsough 
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et al., 2013). Arg817 is located in the juxtamembrane domain and Arg1115 is 
located in the N-terminal end of the kinase domain. Arg817, Lys856, Lys861, and 
Arg1115 methylations appear to have no effect on the phosphorylation or 
function of VEGFR-2. However, methylation of Lys1041 enhances the kinase 
activity of VEGFR-2 (Hartsough et al., 2013). Additionally, methylation at 
Lys1041 is required for VEGFR-2 mediated angiogenesis in zebrafish and for 
VEGFR-2 mediated tumor growth in mouse (Hartsough et al., 2013). Despite the 
importance of methylation of VEGFR-2 in its activation and angiogenesis, the 
specific lysine methyltransferases involved in the methylation of VEGFR-2 are 
not known.   
  
Methyltransferase Activity Regulates Angiogenesis 
 Emerging evidence suggests that methyltransferases play an important 
role in angiogenesis. For example, increased expression of Enhancer of zeste 
homolog 2 (EZH2) is associated with poor cancer prognoses likely because of 
the crucial role it plays in regulating tumor angiogenesis (Crea et al., 2012). In 
ovarian cancer knocking down EZH2 in tumor-associated endothelial cells, which 
typically overexpress EZH2, resulted in decreased tumor growth, mediated 
through vasohibin1 (VASH1) (Lu et al., 2010). Silencing EZH2 lead to increased 
expression of VASH1, which inhibits tumor angiogenesis and tumor growth (Lu et 
al., 2010) (Hosaka et al., 2009). Additionally, in nasopharyngeal carcinomas 
upregulation of EZH2 is correlated with increased microvessel density and poor 
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prognoses (Lu et al., 2014). In this case EZH2 affects angiogenesis through the 
expression of Endothelin-1 (ET-1), which acts as a pro-angiogenic signal (Lu et 
al., 2014). In this same study it was revealed through functional studies that 
EZH2 plays an important role in endothelial cell growth and migration, as well as 
in tubule formation in both in vivo and in vitro studies, further demonstrating 
EZH2’s role in promoting angiogenesis (Lu et al., 2014). EZH2’s direct role in 
angiogenesis has been routinely demonstrated. One potential mechanism for 
EZH2’s role in promoting angiogenesis follows from the finding that EZH2 
methylates and activates STAT3 (Kim et al., 2013). STAT3 is a transcription 
factor that increases expression of VEGF, the ligand required for VEGFR-2 
activation, dimerization, and subsequent kinase activity. It was later shown that 
nuclear transcription factor-Y alpha (NF-YA) upregulates EZH2 and ultimately 
contributes to enhanced tumor angiogenesis mediated through STAT3-EZH2 
signaling (Xu et al., 2016). However, knocking down EZH2 inhibits NF-YA 
induced angiogenesis (Xu et al., 2016). Additionally, it was demonstrated that 
EZH2 is overexpressed in Kaposi sarcoma-associated herpesvirus (KSHV) and 
that this overexpression leads to KSHV induced angiogenesis (He et al., 2012). 
In Kaposi sarcomas and other malignancies related to chronic HIV infections 
EZH2 overexpression enhances expression of Ephrin-B2 by binding to the 
Ephrin-B2 promoter (He et al., 2012). Ephrin-B2 is a pro-angiogenic ligand that 
binds to Ephrin receptors, which ultimately contributes to the enhanced KSHV-
induced tubule formation (He et al., 2012). EZH2 also plays a role in regulating 
	
19 
expression of metalloproteinases (MMP), specifically Mmp9 (Delgado-Olguin et 
al., 2014). Mmp9 is involved with degrading the extracellular matrix. Increased 
Mmp9 expression leads to vascular instability, however EZH2 is able to repress 
expression of Mmp9 thus helping to maintain vascular integrity (Delgado-Olguin 
et al., 2014). Alternatively, expression of EZH2 is known to inhibit angiogenesis 
by reducing expression of endothelial nitric oxide synthase and brain-derived 
neurotrophic factor (eNOS and BDNF), two pro-angiogenic factors (Mitic et al., 
2015). This was demonstrated in ischemic mouse limbs and can be attributed to 
the fact that EZH2 trimethylates lysine 27 on histone H3, which ultimately 
represses gene transcription of these pro-angiogenic signals (Mitic et al., 2015). 
As demonstrated by these studies, EZH2 plays conflicting roles in angiogenesis 
– in some instances it’s been shown to increase angiogenesis and in other 
instances it’s inhibition increases angiogenesis. Because of EZH2’s established 
role in regulating angiogenesis, this project chose to focus EZH2’s potential 






Previous studies have shown that lysine methylation of VEGFR-2 plays a 
critical role in its activation (Hartsough et al., 2013). The overall goal of this thesis 
project was to determine the molecular mechanism of lysine methylation of 
VEGFR-2. Specifically, the goal of this study was to identify the lysine 
methyltransferase involved in the regulation of phosphorylation of VEGFR-2.   
The hypothesis being tested here is that histone-lysine N-methyltransferase 
Enhancer of zeste homolog 2 (EZH2) methylates VEGFR-2 at lysine 1041 and 
increases phosphorylation of VEGFR-2 at Tyr1054.   
The specific aims of this project are as follows: 
 
Specific aim I: Determine that EZH2, through methylation of VEGFR-2, increases 
phosphorylation of VEGFR-2 at Tyr1054. 
Specific aim II: Examine the hypothesis that EZH2 physically interacts with 





Growth Factors and Antibodies 
 Human recombinant macrophage colony stimulating factor-1 (CSF-1) was 
purchased from R&D Systems (Minneapolis, MN). Anti-phospho-VEGFR-2 
Tyr1054 and anti-VEGFR-2 were purchased from Millipore (Temecula, CA). Anti-
EZH2 was purchased from BD Transduction Laboratories (Franklin Lakes, NJ). 
Mouse anti-rabbit IgG HRP-linked secondary antibody and anti-mouse IgG BP- 
HRP linked secondary antibody were both purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA).  
 
Cell Culture 
Human Embryonic Kidney 293, or HEK-293, cells were the primary cell 
line used in this study. HEK-293 cells were made to express a chimeric VEGFR-
2 receptor, called CKR. CKR expressing cells have an intracellular domain 
similar to VEGFR-2 and an extracellular domain that recognizes CSF-1. Cells 
were grown in Dulbecco’s Modification of Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 100IU/100µg/mL (1X) 
Penicillin-Streptomycin Solution (P/S). All cells were incubated at 37°C, 5% CO2, 
in a humidified chamber. At 80-100% confluence, cells were washed in 
Phosphate-buffered saline (PBS), trypsinized, and then split and re-plated for 





 When required cells were serum starved overnight, about 24 hours, and 
then either lysed or stimulated with CSF-1 for 10 minutes at 37°C and then lysed. 
Prior to lysing, cells were washed two times with chilled H/S buffer (25mM 
HEPES, pH 7.4 and 150mM NaCl) while on ice. Cells were lysed in EB lysis 
buffer (10mM Tris-HCl pH 7.5, 10mM EDTA, 50mM NaCl, 50mM NaF, and 1% 
Triton X-100) containing 10µL of 1M sodium orthovanadate (Na3VO4) and 15µL 
of protease inhibitor (PIC) (500µM AEBSF, hydrochloride, 150nM aprotinin, 
bovine lung, crystalline, 1µM E-64 protease inhibitor, 0.5mM EDTA, diodium, and 
1 µM leupeptine, hemisulfate) per every 1mL of EB lysis buffer. Cells were 
centrifuged, the supernatant was treated with 5X Sample Buffer (3.8% Tris-base, 
50% glycerol, 5% sodium dodecyl sulphate (SDS), 5% b-mercaptoethanol, and 
.0025% bromophenol blue), and then heated to 95°C for 5 minutes. Cell lysates 
were resolved on a 7.5% SDS-polyacrylamide gel by electrophoresis (SDS-
PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane activated 
with methanol. The PVDF membrane was blocked with Blotto for 1 hour (2% 
non-fat dry milk and 0.05% Tween-20 in Western Rinse), washed in western 
rinse, and then immunoblotted with the antibody of interest for at least 1 hour. 
Primary antibodies were diluted in Block (2% bovine serum albumin (BSA) and 
0.05% Tween-20 in Western Rinse). Anti-pY1054 was diluted to 1:1,000, anti-
EZH2 was diluted to 1: 1,000, and anti-VEGFR-2 was diluted to 1: 10,000. 
Secondary antibodies were diluted in Blotto. Anti-rabbit-IgG HRP-linked 
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secondary antibody and anti-mouse-IgG BP-HRP-linked secondary antibody 
were both diluted to 1:10,000. Membranes were developed with enhanced 
chemiluminescence (ECL) made in house. When needed, membranes were 
stripped by incubating with stripping buffer (1M Tris-HCl pH6.8, 20% SDS, and b-
Mercaptoethanol (690µL/100mL)) for 30 minutes at 50°C, washed in western 
rinse for 30 minutes, blocked for 1  hour, and then re-probed for the protein of 
interest.  
Cell Transfection 
CKR/HEK-293 cells seeded in 60mm plates were transfected with 3µg of 
pcDNA3.1-myc empty vector, Acd, ESET1, EZH1, EZH2, G9A, MD14, M115, or 
SUV39H1 and 9µL of polyethylenimine (PEI) in preliminary trials. Cells were 
serum starved for 6 hours while transfection took place and then given DMEM 
10%FBS P/S. When necessary, cells were starved for 24 hours and either lysed 
or stimulated with CSF-1 for 10 minutes and then lysed. Lysates underwent 
western blot analysis probing for pY1054 and VEGFR-2. In later trials CKR/HEK-
293 cells were transfected with 3µg or 6µg of pcDNA3.1-myc empty vector, 
EZH2, G9A, or SUV39H1 with 9µL or 18µL of PEI respectively. Cells were then 
starved, stimulated with CSF-1, lysed, subject to western blot analysis, and 
probed with anti-pY1054 and anti-VEGFR-2. Finally, CKR/HEK-293 cells seeded 
on 10cm plates were transfected with 9µg of pcDNA3.1-myc empty vector or 
EZH2 and 27µL of PEI, lysed after stimulation, immunoprecipitated with anti-
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VEGFR-2, subject to western blot analysis, and probed with anti-pY1054 
antibody, anti-VEGFR-2 antibody, and anti-EZH2 antibody. Table 1 lists the 
KMTs and the amounts used in cell transfection experiments. Also noted is the 
concentration of DNA for each plasmid.  
Table 1: CKR/HEK-293 Transfection Materials. 
KMT Plasmid 
Name 








Acd 7.25µL at .414µg/µL N/A N/A 
ESET1 2.58µL at 1.16µg/µL N/A N/A 
EZH1 2.56µL at 1.17µg/µL N/A N/A 




G9A 2.73µL at 1.10µg/µL 5.45µL at 
1.10µg/µL 
N/A 
MD14 11.90µL at 
0.25µg/µL 
N/A N/A 
M115 1.89µL at 1.59µg/µL N/A N/A 





 CKR/HEK-293 cells transfected with pcDNA3.1-myc empty vector or 
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EZH2 seeded on 10cm cell plates were lysed as previously described. Lysates 
were incubated with 5µL of anti-VEGFR-2 primary antibody in a rotating 
incubator overnight, about 20 hours, at 4°C. 40µL of Protein A-Sepharose beads 
(purchased from Sigma, St. Louis, MO) were added and lysates were rotated in 
incubator at 4°C for 2-3 hours. Lysates were washed 3 times with EB Lysis Buffer 
containing sodium orthovanadate and PIC. The remaining bead slurry was 
treated with 2X Sample Buffer, heated to 95°C for 5 minutes, resolved on SDS-
PAGE, transferred to a PVDF membrane, and then probed with anti-pY1054,  
anti- VEGFR-2, and anti-EZH2 antibodies.  
GST Pull down Assay 
E. coli BL21 bacteria were transformed with EZH2 plasmids – EZH2 N-
terminus 1-370 amino acids and EZH2 C-terminus 371-746 amino acids obtained 
from Dr. Reinberg from NYU Medical Center (Kaneko et al., 2010). Bacteria was 
grown in 200mL of Lysogeny broth (LB) medium plus Ampicillin, shaking at 37°C 
for about 18 hours. 1mL of Isopropyl b-D-1-thiogalactopyranoside (IPTG) was 
added and bacteria were incubated again on the shaker at 37°C for 4 hours. 
Bacteria was centrifuged for 30 minutes at 5000rpms at 4°C, the supernatant 
was removed, and the pellet was stored in a -20°C freezer overnight. The pellet 
was resuspended in 5mL of PBS containing PIC and the cells were disrupted by 
sonication. Cells were incubated on ice for 30 minutes in a 1% solution of Triton-
X-100. The solution underwent centrifugation at 5000rpms for 30 minutes at 4°C 
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and the supernatant was collected. 500µL of mixed PBS and Glutathione 
Sepharose beads were added to each supernatant. The bead slurry was 
incubated in a rotator incubator at 4°C for 3 hours and then stored at 4°C until 
use. Presence of protein was confirmed through SDS-PAGE stained with 
Coomassie Blue Stain. 
 100µL of GST-EZH2 1-370 and 75µL of GST-EZH2 370-746 were added 
separately to 1mL of cell lysate for each, collected as described above. 
Additionally, 10µL of GST-PGEX 4T-2 control was added to a separate cell 
lysate. Lysates and GST-fusion protein mix were incubated in a rotator incubator 
at 4°C overnight, about 24 hours. Lysates were washed 3 times in EB Lysis 
Buffer with Na3VO4 and PIC. Lysates were then subject to Western Blot analysis 




Overexpression of EZH2 Increases Phosphorylation of VEGFR-2 in a 
Concentration Dependent Manner 
To determine which KMT is responsible for methylation of Lys1041, 
CKR/HEK-293 cells were transfected with various KMTs. CKR is a chimeric 
VEGFR-2 receptor with its intracellular domain the same as VEGFR-2 and its 
extracellular domain recognizing human recombinant macrophage colony 
stimulating factor-1 (CSF-1). Cells expressing CKR, rather than VEGFR-2, were 
used to control for affects caused by VEGFR-2. Both VEGFR-2 and VEGFR-1 
become activated in response to the same ligand – VEGF, hence the need for a 
chimeric receptor. CKR/HEK-293 cells seeded on 60mm plates were transfected 
with 3µg of pcDNA3.1-myc empty vector (referred to as the control), Acd, ESET1, 
EZH1, EZH2, G9A, MD14, M115, or SUV39H1. Cells were stimulated for 10 
minutes with CSF-1 prior to lysing. Lysates were subject to western blot analysis 
probing for anti-pY1054 and anti-VEGFR-2 (data not shown). Looking at the 
relative phosphorylation of Tyr1054 compared to the stimulated control group, 
EZH2, G9A, and SUV39H1 were selected to be transfected at varying amounts - 
3µg and 6µg of DNA. These KMTs were chosen based off of preliminary data 
suggesting increased phosphorylation of pY1054 due to overexpression of KMTs 
compared to empty vector pY1054 expression, however this data was not 
consistent over several independent trials likely due to experimental error. 
Additionally, these KMTs were chosen to be further investigated due to evidence 
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suggesting they exist outside of the nucleus and thus have the possibility to 
interact with VEGFR-2. EZH2 is known to play a role in regulating angiogenesis, 
hence the initial choice to focus on this KMT.  
Cells were transfected with either 6µg of pcDNA3.1-myc empty vector, 
3µg or 6µg of EZH2, 3µg or 6µg of G9A, or 3µg or 6µg of SUV39H1. Again the 
cells were starved, stimulated, lysed, subject to western blot analysis, and 
probed with anti-pY1054 and anti-VEGFR-2 antibodies. In 3 separate trials EZH2 
overexpression lead to increased phosphorylation at Tyr1054, a representative 
blot is shown in Figure 3A and the average phosphorylation of Tyr1054 across 
the 3 experiments is shown in Figure 3 B. ImageJ software was used to 
quantitatively determine pY1054 levels relative to the total VEGFR-2. Cells 
transfected with empty vector, stimulated, and then lysed were used as the 
control for detection of pY1054, and consequently were set at a base of 1 
arbitrary unit. The blots from 3 independent experiments were quantified using 
ImageJ software and then the ratio of pY1054 to the total VEGFR-2 was 
calculated. On average transfection with 3µg of EZH2 resulted in 2.66 au 
(arbitrary unit) of pY1054 expression compared to 1 au of pY1054 expression for 
cells transfected with the empty vector with a standard deviation of 1.77. The 
average expression of pY1054 in cells transfected with 6µg of EZH2 was 5.26 
au, again compared to 1 au for cells transfected with empty vector with a 
standard deviation of 1.27. Figure 3B is a graphical representation of the average 
pY1054 expression across three trials including error bars indicating 1 standard 
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deviation above and below the averages. Note that transfecting with 6µg of EZH2 
lead to more phosphorylation of Y1054 compared to transfection with 3µg of 
EZH2 (Figure 3A). To confirm successful transfection at the increasing amounts 
of EZH2, lysates were also probed for anti-EZH2. In 3 separate trials EZH2 
expression was greater in cells transfected with 6µg of EZH2 compared to cells 
transfected with 3µg of EZH2. Hence, EZH2 overexpression increases 




Figure 3: EZH2 Overexpression Increases Phosphorylation of VEGFR-2 in 
Whole Cell Lysates in a Concentration Dependent Manner. A) CKR/HEK-293 
cells transfected with pcDNA3.1-myc empty vector or EZH2 plasmids were 
subject to western blot analysis and probed with anti-pY1054, anti-VEGFR-2, and 
anti-EZH2. There is increased detection of pY1054 in CKR/HEK-293 cells 
overexpressing EZH2 compared to cells transfected with empty vector. The anti-
VEGFR-2 blot represents the loading control. In the anti-EZH2 blot there is 
increasing detection of EZH2 consistent with the increasing amount of EZH2 
used for transfection. B) Expression of pY1054 and VEGFR-2 in western blots 
was quantified using ImageJ software, the relative expression of pY1054 was 
calculated, expression levels were standardized around the stimulated control set 
at 1, the data from 3 separate trials was averaged and the standard deviation 
was calculated, and finally the data was graphed. Error bars represent 1 
standard deviation above and below the mean. Note the increasing expression of 
pY1054 in cells transfected with 3µg of EZH2 and 6µg of EZH2 compared to cells 




 To further evaluate the role of EZH2 in methylation of Lys1041, CKR-HEK-
293 cells seeded on 10cm plates were transfected with 9µg of EZH2 or the 
control, pcDNA3.1-myc empty vector. Cells were starved and lysed without 
stimulation or, stimulated with CSF-1 and lysed. Cell lysates were 
immunoprecipitated with anti-VEGFR-2, subject to western blot analysis, and 
probed for anti-pY1054 and anti-VEGFR-2. As seen in Figure 4A, 
phosphorylation at Tyr1054 is greater in stimulated cells transfected with EZH2 
compared to cells transfected with empty vector. Figure 4B represents the 
quantified relative increase in phosphorylation of Tyr1054 in cells transfected with 
EZH2 compared to control cells. With the relative phosphorylation of Tyr1054 of 
stimulated control cells set to 1 au, cells transfected with EZH2 expressed 
pY1054 at a level of 5.39 au. Hence, in cells immunoprecipitated with anti-
VEGFR-2, EZH2 overexpression leads to increased phosphorylation of Tyr1054 




Figure 4: EZH2 Overexpression Increases Phosphorylation of VEGFR-2 
Purified by Immunoprecipitation with Anti-VEGFR-2. A) CKR/HEK-293 cells 
were transfected with pcDNA3.1-myc empty vector or EZH2. Cell were either 
serum starved and lysed or serum starved, stimulated with CSF-1, and lysed. 
Lysates were immunoprecipitated with anti-VEGFR-2 antibody, subject to 
western blot analysis, and probed for pY1054 and VEGFR-2. Note increased 
pY1054 in EZH2 transfected, stimulated cells compared to control stimulated 
cells. Also note expression of EZH2 in whole cell lysates, WCL, indicating 
successful transfection. B) Graphical representation of the relative increase in 
phosphorylation at Tyr1054 in EZH2 transfected cells compared to control cells. 
pY1054 and VEGFR-2 expression were measured using ImageJ software, the 
relative expression of pY1054 was calculated, the results were standardized 
around the control (pcDNA3.1-myc empty vector stimulated cells), and the results 
were graphed. Note increased phosphorylation at Tyr1054 in EZH2 transfected 




EZH2 Binds to VEGFR-2 in a Ligand Independent Manner  
 
To assess whether EZH2 interacts with VEGFR-2, CKR-HEK-293 cells 
were transfected with either EZH2 or pcDNA3.1-myc empty vector, serum-
starved, stimulated with CSF-1 for 10 minutes, and then lysed. Lysates were 
immunoprecipitated with anti-VEGFR-2 antibody, and subject to western blot 
analysis using anti-VEGFR-2 and anti-EZH2 antibodies. Whole cell lysates were 
also subject to western blot analysis probing with anti-EZH2 antibody (Figure 
5A). Figure 5A demonstrates the expression of EZH2 in cells stimulated with 
CSF-1, lysed, and immunoprecipitated with anti-VEGFR-2. This finding 
concludes that EZH2 interacts with ligand-stimulated VEGFR-2. Next it was 
examined whether EZH2 interacts with VEGFR-2 without ligand stimulation 
(Figure 5B). This was found by transfecting cells with EZH2 or empty vector and 
then starving and lysing or starving, stimulating, and then lysing. Again, as a 
control, CKR/HEK-293 cells were transfected with EZH2, starved, stimulated, 
lysed, and subject to western blot analysis probing for anti-EZH2 and anti-
VEGFR-2. This control group is represented by WCL. Experimental groups were 
immunopreicpitated with anti-VEGFR-2 and then subject to western blot analysis 
probing for anti-EZH2 and anti-VEGFR-2. As demonstrated in Figure 5B, both 
stimulated and unstimulated CKR/HEK-293 cells transfected with EZH2 and then 
immunoprecipitated with anti-VEGFR-2 express EZH2 suggesting EZH2 binds 





Figure 5: EZH2 Binds to VEGFR-2 in a Ligand Independent Manner. A) 
CKR/HEK-293 cells transfected with pcDNA3.1-myc empty vector or EZH2 were 
serum starved, stimulated, and then lysed. Lysates from the EZH2 transfected 
group and the control group were immunoprecipitated with anti-VEGFR-2 
antibody. Additional lysates from the EZH2 transfected group were subject to 
western blot analysis without immunoprecipitation, referred to here as whole cell 
lysates (WCL). The membrane was probed for anti-EZH2 and anti-VEGFR-2. 
Note expression of EZH2 in both groups transfected with EZH2 – WCL and cells 
immunoprecipitated with anti-VEGFR-2, concluding EZH2 interacts with VEGFR-
2.  B) To determine if EZH2 binds VEGFR-2 independent of ligand stimulation or 
not, again CKR/HEK-293 cells were transfected with either pcDNA3.1-myc empty 
vector or EZH2. Cells transfected with the control were serum starved, 
stimulated, and lysed. Cells transfected with EZH2 were either serum starved 
and lysed or serum starved, stimulated, and then lysed. One group of EZH2 
transfected, stimulated cells did not undergo immunoprecipitation and is noted in 
Figure 5B as WCL. The remaining lysates were immunoprecipitated with anti-
VEGFR-2 antibody and subject to western blot analysis probing for anti-EZH2 
and anti-VEGFR-2. This blot demonstrates that EZH2 binds VEGFR-2 




C-Terminal Domain of EZH2 Interacts with VEGFR-2 
To determine the precise binding of EZH2 with VEGFR-2, GST-EZH2 
constructs composed of the N-terminus represented by amino acids 1-370 and 
GST-EZH2 constructs composed of the C-terminus represented by amino acids 
371-746 were used. Plasmids were kindly provided by Dr. Reinberg, NYU 
Medical Center. The GST-EZH2 constructs were purified using a GST-
purification system. CKR/HEK-293 cells were lysed and then either GST-PGEX 
4T-2, GST-EZH2 1-370aa, or GST-EZH2 371-746aa bead slurry was added to 
the lysates. GST-PGEX represents the control GST group while WCL represents 
cells not pulled down with GST-fusion proteins. Binding with GST-fusion beads 
occurred over 24 hours as the lysates and bead slurry mixed on a rotator 
incubator at 4°C. Finally, the lysates were washed 3 times with lysis buffer and 
then subject to western blot analysis and probed with anti-VEGFR-2 antibody. As 
demonstrated in Figure 6, cell lysates incubated with GST-EZH2 371-746aa were 
positive for VEGFR-2, indicating that the C-terminus of EZH2 interacts with 
VEGFR-2. This result was confirmed in three separate trials. The binding was 
relatively weak suggesting that either the washing condition was harsh or the full-





Figure 6: C-Terminal Domain of EZH2 Interacts with VEGFR-2. CKR/HEK-
293 cells were lysed and then incubated with GST-PGEX, GST-EZH2 1-370aa, 
or GST-EZH2 371-746aa overnight in a rotating incubator at 4°C. As a control 
group CKR/HEK-293 cells were lysed and immediately subject to western blot 
analysis probing for anti-VEGFR-2, represented in Figure 6 as WCL, or whole 
cell lysate. Note expression of VEGFR-2 in lysates incubated with GST-EZH2 
371-746 and similar expression of VEGFR-2 in WCL. This suggests that the C-
terminus of EZH2, or amino acids 371-746, interacts with VEGFR-2 rather than 





 Blood vessels are maintained and extended through the process of 
angiogenesis. As discussed in the introduction, new blood vessel development is 
required for both normal and pathological tissues. VEGFR-2 plays an important 
role in this process by responding to pro-angiogenic signals such as VEGF 
ligand. A key step in activating VEGFR-2 in angiogenesis is the 
autophosphorylation of Tyrosine residues in the activation loop of the receptor, 
which occurs upon ligand binding. Without this step the ATP binding pocket is 
inhibited and VEGFR-2 cannot carry out its role as a receptor tyrosine kinase. 
Recent studies have demonstrated protein methylation as a critical step in 
controlling Tyrosine autophosphorylation of VEGFR-2. Namely, Lysine1041 
methylation promotes Tyrosine autophosphorylation (Hartsough et al., 2013). 
Hartsough revealed methylation of Lys1041 as a requirement for VEGFR-2 
mediated angiogenesis in zebrafish and tumor growth in mouse (Hartsough et 
al., 2013). The goal of this project was to identify the Lysine Methyltransferase, or 
KMT, responsible for methylation of VEGFR-2.  
 Because methylation at site Lys1041 plays such a critical role in promoting 
phosphorylation of VEGFR-2, specifically at Tyrosine1054, phosphorylation of 
Tyr1054 was used to measure lysine methylation. Ideally, and in the future, mass 
spectrometry analysis should be performed in order to confirm differences in 
methylation patterns. Alternatively, antibodies specific for methylated sites could 
be used to confirm methylation differences between control and KMT transfected 
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groups.  Initially several KMT’s were transfected into CKR/HEK-293 cells. CKR is 
a chimeric VEGFR-2 receptor with its intracellular domains similar to VEGFR-2 
and its extracellular domain recognizing human recombinant macrophage colony 
stimulating factor-1, CSF-1. Prior to lysing cells were starved for 24 hours and 
stimulated with CSF-1 for 10 minutes in order to activate VEGFR-2. 
Phosphorylation of Tyr1054 was measured using western blot analysis probing 
for anti-pY1054 and anti-VEGFR-2, as a loading control. Phosphorylation of 
Y1054 was compared in each experimental group to the control group – 
CKR/HEK-293 cells transfected with pcDNA3.1 empty vector. Three KMTs were 
selected to be transfected in varying amounts in order to better assess how 
overexpressing a KMT affected pY1054 expression. EZH2, G9A, and SUV39H1 
were selected based off of preliminary data as well as evidence suggesting these 
KMTs exist outside of the nucleus (Venkatesan et al., 2018; Brown et al., 2001; 
Kamoi et al., 2006) and thus have the capability to act on VEGFR-2. Additionally, 
EZH2 was selected due to its known role in regulating angiogenesis (Crea et al., 
2012). After transfection with both 3 and 6µg of DNA for each group, it was noted 
in three separate trials that transfection with EZH2 resulted in increased pY1054 
expression compared to cells transfected with empty vector. Additionally, as 
demonstrated in Figure 3, transfection with 6µg of EZH2 resulted in increased 
pY1054 expression compared to transfection with 3µg of EZH2. This resulted in 
the conclusion that EZH2 increases phosphorylation of VEGFR-2 in a 
concentration dependent manner.  
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 Next it was determined that EZH2 physically interacts with VEGFR-2 and 
its interaction with VEGFR-2 was independent of VEGFR-2 phosphorylation. This 
was concluded using immunoprecipitation with anti-VEGFR-2 and then western 
blot analysis probing for anti-EZH2 and anti-VEGFR-2. Figure 5 shows the 
expression of EZH2 in lysates immunoprecipitated with anti-VEGFR-2. This 
technique allows such conclusions to be made because following incubation with 
antibody and Protein A Sepharose beads, which bind the antibody, lysates were 
washed thoroughly. This step washes away any protein or debris unbound to the 
antibody and consequently the sepharose beads. The remaining bead slurry is 
subject to western blot analysis. Given that anti-VEGFR-2 was the antibody used 
in immunoprecipitation, it can be assumed that only VEGFR-2 and proteins 
interacting with VEGFR-2 remained in the bead slurry. Visualizing EZH2 in 
western blot analysis allows for the conclusion that EZH2 interacts with VEGFR-
2. This was investigated further by including two groups of lysates – those 
transfected with EZH2 and non-stimulated and those transfected with EZH2 and 
then stimulated. Again using immunoprecipitation, it was found that EZH2 
interacts with VEGFR-2 regardless of VEGFR-2 activation. This confirms what is 
known regarding methylation of VEGFR-2 – methylation occurs 
posttranslationally, but independent of receptor activation.  
 To further investigate how EZH2 interacts with VEGFR-2, truncated 
versions of EZH2 plasmids were obtained from Dr. Reinberg out of New York 
University School of Medicine. EZH2 was separated into two parts – the N-
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terminus represented by amino acids 1-370 and the C-terminus represented by 
amino acids 371-746. These plasmids were transformed into BL21 bacteria, 
which increased expression of the truncated proteins. The proteins were purified 
using GST-purification and then confirmed by running an SDS-PAGE and 
staining with Coomassie blue stain. With the truncated proteins attached to GST 
beads a GST pulldown assay was performed. CKR/HEK-293 cells were lysed, 
without stimulation, and then incubated with either GST-PGEX, GST-EZH2 1-
370aa, or GST-EZH2 371-746aa. GST-PGEX represented the control GST 
group. After incubation and extensive washing with lysis buffer the GST-bead 
slurry was subject to western blot analysis probing for anti-VEGFR-2. Similarly to 
immunoprecipitation, only protein bound to the GST fusion protein remains in the 
bead slurry after washing and thus only this protein will be detectable using 
western blot analysis. EZH2’s catalytically active SET domain resides in the C-
terminus; thus it was hypothesized that the N-terminus physically interacts with 
VEGFR-2 while the C-terminus catalyzes the addition of a methyl group from 
SAM. As demonstrated in Figure 6, this hypothesis was proven incorrect. GST-
EZH2 370-746 interacted with VEGFR-2 as demonstrated by the presence of 
VEGFR-2 expression in lysates pulled down with GST-EZH2 371-746 in three 
separate trials, one shown in Figure 6. The binding of GST-EZH2 371-746 to 
VEGFR-2 appeared relatively weak in all three trials suggesting washing 
conditions may have been too harsh or the whole EZH2 protein is required for 
optimal binding to VEGFR-2. 
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 In conclusion, overexpression of EZH2 increased phosphorylation of 
VEGFR-2. Previous studies have shown that methylation of K1041 increases 
phosphorylation of Tyr1054 (Hartsough et al., 2013), thus increased 
phosphorylation of VEGFR-2 suggests increased methylation of VEGFR-2 at 
Lys1041. However, the direct role of EZH2 on the methylation of VEGFR-2 
needs to be determined via mass spectrometry analysis or antibodies specific for 
methyl-Lys1041. The findings that increased EZH2 expression leads to increased 
phosphorylation of VEGFR-2 at Tyr1054 is supported by the finding that EZH2 
physically interacts with VEGFR-2 through its C-terminal domain. To gain an 
increased understanding of how EZH2 affects the process of angiogenesis, 
EZH2 could be knocked down or overexpressed in endothelial cells and the 
effect on the capillary tube formation determined. It’s currently known that EZH2 
plays a role in angiogenesis by methylating and activing STAT3, a transcription 
factor that increases VEGF expression (Xu et al., 2016). Additionally, EZH2 
overexpression leads to increased cell growth, migration, and tubule formation 
whereas knocking down EZH2 resulted in the opposite – inhibited cell growth, 
migration, and tubule formation in human umbilical vein endothelial cells 
(HUVEC) (Lu et al., 2014). The findings from this project suggest a novel 
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